Regenerative Medicine / Orthobiologics

What Is Regenerative Medicine?

Regenerative medicine is an evolving area of healthcare that investigates the use of biological therapies to support the body’s normal tissue repair processes. Within musculoskeletal medicine, these approaches are being explored as non-surgical treatment options for selected tendon, ligament, muscle, cartilage, bone and joint conditions, particularly where symptoms have persisted despite appropriate conservative management.

Many of these procedures are referred to as orthobiologics. Orthobiologics are biological preparations used in the management of musculoskeletal conditions with the aim of influencing the local biological environment involved in tissue repair. Common examples include Platelet-Rich Plasma (PRP), Bone Marrow Aspirate (BMA), Bone Marrow Aspirate Concentrate (BMAC) and, in selected clinical settings, adipose-derived tissue preparations. Many orthobiologic procedures use the patient’s own (autologous) biological tissues, reducing the risk of immune rejection.

How Do Orthobiologics Work?

Orthobiologic preparations contain naturally occurring cells, platelets, growth factors and other signalling molecules that participate in the body’s normal response to tissue injury. Rather than directly replacing damaged tissue, these biological components are thought to influence cellular communication, inflammatory pathways and the local biological environment involved in tissue repair.

The precise mechanisms differ between procedures and continue to be investigated.

For example, Bone Marrow Aspirate Concentrate (BMAC) contains a complex mixture of mesenchymal stromal cells (MSCs), haematopoietic stem and progenitor cells, platelets, cytokines, growth factors and other biologically active molecules. Current scientific understanding suggests that any potential clinical effects are more likely related to the combined signalling and regulatory functions of these biological components than to the direct formation of new cartilage, tendon or bone.

Laboratory and preclinical studies have demonstrated a range of biological activities; however, translating these findings into consistent clinical outcomes remains an active area of research.

What Does the Evidence Show?

Research into orthobiologic procedures has expanded considerably over the past decade. The strength of evidence varies according to the specific procedure, the condition being treated and patient selection.

Current evidence suggests Platelet-Rich Plasma (PRP) may provide benefit for selected patients with some chronic tendinopathies and mild to moderate osteoarthritis.

For other orthobiologic procedures, including Bone Marrow Aspirate Concentrate (BMAC), early clinical studies have reported encouraging findings in selected musculoskeletal conditions. However, further high-quality clinical trials are required to better define patient selection, preparation methods, treatment protocols and long-term outcomes.

Current evidence does not support claims that orthobiologic procedures can reliably regenerate damaged articular cartilage, reverse advanced osteoarthritis or guarantee tissue healing.

Our Clinical Approach

Orthobiologic procedures are considered one component of a comprehensive musculoskeletal management plan rather than a stand-alone treatment.

Where clinically appropriate, they may be incorporated alongside:

  • Comprehensive clinical assessment
  • Accurate diagnosis
  • Patient education
  • Exercise-based rehabilitation
  • Activity modification
  • Lifestyle measures
  • Ongoing clinical review

Treatment recommendations are individualised following consideration of the patient’s diagnosis, clinical presentation, functional goals, current scientific evidence and personal preferences.

Not every patient is an appropriate candidate for an orthobiologic procedure. As with all healthcare interventions, treatment responses vary between individuals. Before proceeding, the potential benefits, limitations, known risks, costs and reasonable alternative management options should be discussed as part of an informed consent process.

Advances in diagnostic musculoskeletal ultrasound and orthobiologic procedures have expanded the range of management options available for some musculoskeletal conditions. When incorporated into an evidence-informed management plan, these approaches may assist selected patients in managing pain, improving function and supporting their rehabilitation. Treatment selection should always be guided by comprehensive clinical assessment, current evidence and shared decision-making.

Regenerative Medicine

Regenerative Medicine

Regenerative medicine is an evolving area of healthcare that investigates the use of biological therapies to influence the body’s normal tissue repair processes. Within musculoskeletal medicine, these procedures are commonly referred to as orthobiologic procedures because they use naturally occurring biological components—such as platelets, cells, growth factors and signalling molecules—obtained from a patient’s own tissues.

Orthobiologic procedures are being investigated as non-surgical treatment options for selected musculoskeletal conditions, particularly where symptoms have persisted despite appropriate conservative management. Current evidence suggests that some procedures may provide benefit for appropriately selected patients and conditions, including improvements in pain and function. However, the strength of evidence varies between procedures and clinical indications, and research continues to evolve.

Potential Benefits

Depending on the condition being treated, the individual patient and the specific orthobiologic procedure used, potential benefits reported in clinical studies may include:

  • Improvements in pain for some patients
  • Improvements in function and movement
  • Influencing the local biological environment involved in tissue repair
  • Supporting participation in rehabilitation and return to meaningful activities
  • Improvements in health-related quality of life for some individuals

Treatment responses vary considerably between individuals, and not every patient will experience the same degree of benefit. No orthobiologic procedure can guarantee a specific clinical outcome.

A Comprehensive Management Approach

Orthobiologic procedures are considered one component of a comprehensive musculoskeletal management plan rather than a stand-alone treatment.

Where clinically appropriate, they may be incorporated alongside:

  • Comprehensive clinical assessment and accurate diagnosis
  • Patient education
  • Exercise-based rehabilitation
  • Biomechanical assessment
  • Activity modification
  • Lifestyle measures where appropriate
  • Ongoing clinical review

Treatment recommendations are individualised following consideration of the patient’s diagnosis, clinical presentation, functional goals, current scientific evidence and personal preferences. Shared decision-making and informed consent are important components of determining whether an orthobiologic procedure is appropriate.

Common Musculoskeletal Conditions

Conditions That May Be Considered

Following a comprehensive clinical assessment, orthobiologic procedures may be considered as part of an individualised management plan for selected patients with conditions including:

  • Osteoarthritis
  • Tendinopathy, including tennis elbow, golfer’s elbow and Achilles tendinopathy
  • Plantar fasciitis
  • Selected ligament injuries
  • Selected muscle injuries
  • Rotator cuff tendinopathy
  • Greater trochanteric pain syndrome (gluteal tendinopathy)
  • Patellar tendinopathy
  • Chronic joint pain
  • Selected spinal and sacroiliac joint pain syndromes
  • Some persistent musculoskeletal conditions that have not responded adequately to appropriate conservative management

Whether an orthobiologic procedure is appropriate depends on the individual’s diagnosis, clinical assessment, imaging findings where indicated, medical history, functional goals, current scientific evidence and personal preferences.

During your consultation, your practitioner will discuss the potential benefits, known limitations, risks, costs and reasonable alternative management options to support informed decision-making.

As with all healthcare interventions, not every patient is an appropriate candidate for an orthobiologic procedure. Treatment responses vary between individuals, and no procedure can guarantee a specific clinical outcome.

Our Approach to Regenerative Medicine

The management of musculoskeletal conditions such as osteoarthritis, tendon disorders and sports injuries often involves a combination of evidence-informed treatments, including patient education, exercise-based rehabilitation, activity modification, manual therapy, analgesic and anti-inflammatory medications and, where appropriate, injection therapies or surgery.

While these approaches can be effective in reducing pain and improving function, treatment plans are individualised and depend on the nature and severity of the condition, the patient’s goals and the available evidence.

Orthobiologic therapies are an evolving area of regenerative medicine that aim to support the body’s natural tissue repair processes. These treatments utilise biological components obtained from the patient’s own tissues, including platelets, cells, growth factors and signalling molecules, with the intention of supporting the local biological environment involved in tissue repair.

Inflammation is a normal part of the body’s response to tissue injury. Current research suggests that orthobiologic therapies may influence aspects of the inflammatory response and cellular signalling involved in tissue repair. The precise biological mechanisms and their relationship to clinical outcomes continue to be investigated, and treatment responses vary between individuals and conditions.

Many patients who attend our practice have persistent musculoskeletal symptoms despite appropriate conservative management. These may include osteoarthritis, tendon and ligament disorders, sports injuries and other chronic musculoskeletal conditions.

A regenerative medicine consultation begins with a comprehensive clinical assessment, which may include a detailed history, physical examination and, where appropriate, diagnostic musculoskeletal ultrasound or review of relevant imaging. The aim is to establish an accurate diagnosis, identify contributing biomechanical and lifestyle factors, and determine whether an orthobiologic therapy may be an appropriate component of the overall management plan.

Where suitable, an individualised treatment program is developed that may incorporate orthobiologic therapies alongside exercise-based rehabilitation, activity modification, patient education and ongoing clinical review. The choice of treatment is guided by the patient’s diagnosis, current evidence, functional goals, general health and personal preferences.

Before proceeding with treatment, patients are provided with information regarding the potential benefits, limitations, risks, costs and alternative management options to support informed decision-making.

As with all healthcare interventions, not every patient is an appropriate candidate for orthobiologic therapy, and no treatment can guarantee a particular outcome.

Choosing the Appropriate Orthobiologic

Selecting the most appropriate orthobiologic is an important part of developing an individualised treatment plan. No single biological therapy is suitable for every musculoskeletal condition, and treatment selection depends on a combination of clinical findings, diagnostic imaging, the severity and duration of symptoms, previous treatments, overall health, functional goals and the current scientific evidence.

Following a comprehensive assessment, your practitioner will discuss the available treatment options, together with the potential benefits, limitations, risks and expected rehabilitation requirements, to determine whether an orthobiologic therapy is an appropriate component of your overall management plan.

Platelet-Rich Plasma (PRP)

Platelet-rich plasma (PRP) is one of the most extensively researched orthobiologic therapies used in musculoskeletal medicine. PRP is produced by concentrating platelets from a patient’s own blood before the platelet-rich fraction is injected into the affected tissue, typically under ultrasound guidance where appropriate.

Platelets contain numerous growth factors, cytokines and bioactive proteins that are involved in the body’s normal response to tissue injury. These biological mediators are believed to influence cellular signalling, collagen remodelling, angiogenesis and other processes associated with tissue repair. Although the biological mechanisms continue to be investigated, PRP is thought to support the local biological environment involved in healing rather than directly regenerating damaged tissue.

Current evidence supports the use of PRP for selected chronic tendinopathies and for some patients with mild to moderate osteoarthritis. Clinical studies have demonstrated improvements in pain and function for appropriately selected patients; however, treatment responses vary and outcomes cannot be predicted for every individual.

As PRP is prepared from the patient’s own blood (autologous), the risk of immune reaction is minimal. Treatment is usually performed as an outpatient procedure and is commonly combined with an individualised rehabilitation program.

Research continues to refine patient selection, preparation methods, platelet composition and treatment protocols to better understand which patients are most likely to benefit.

Bone Marrow Aspirate Concentrate (BMAC)

Bone marrow aspirate concentrate (BMAC) is an autologous orthobiologic produced by concentrating cells and biological components obtained from a patient’s own bone marrow, most commonly from the posterior iliac crest (pelvis).

BMAC contains a diverse population of cells and biological mediators, including mesenchymal stromal cells (MSCs), haematopoietic stem and progenitor cells, platelets, cytokines, growth factors and other signalling molecules involved in normal tissue repair.

Current scientific understanding suggests that any potential clinical effects are primarily related to the signalling and regulatory functions of these biological components rather than the direct formation of new cartilage, tendon or other tissues.

It is important to understand that BMAC is not a purified stem cell treatment. Rather, it is a complex cellular concentrate containing multiple cell populations together with numerous biologically active proteins that work collectively within the local tissue environment. The contribution of each component and the mechanisms responsible for any clinical effects continue to be actively investigated.

BMAC has been studied in selected musculoskeletal conditions, including osteoarthritis, focal cartilage lesions, certain tendon disorders and some bone-related conditions. While early clinical studies have reported encouraging findings, further high-quality clinical trials are required to better define patient selection, treatment protocols and long-term outcomes.

Alpha-2-Macroglobulin (A2M)

Alpha-2-macroglobulin (A2M) is a naturally occurring protein found in blood plasma that plays an important role in regulating enzymes involved in normal tissue turnover.

In osteoarthritis, increased activity of certain proteolytic enzymes has been associated with progressive cartilage degeneration. Laboratory and preclinical studies suggest that A2M may inhibit some of these enzymes, resulting in interest in its potential role as an orthobiologic treatment for degenerative joint disease.

At present, clinical evidence supporting A2M remains limited. Further well-designed clinical studies are required to establish its effectiveness, identify appropriate patient selection and define its role within musculoskeletal medicine.

Evidence-Informed Treatment Selection

Regenerative medicine and orthobiologic therapies continue to evolve as new clinical evidence becomes available. The strength of evidence differs between individual therapies and the conditions for which they are used. Consequently, treatment recommendations are based on a combination of:

  • A comprehensive clinical assessment.
  • An accurate diagnosis.
  • Diagnostic imaging where appropriate.
  • Current scientific evidence.
  • Patient safety and medical suitability.
  • Functional goals and expectations.
  • Shared decision-making and informed consent.

Orthobiologic therapies are considered one component of a comprehensive musculoskeletal management strategy and, where appropriate, may be integrated with education, exercise-based rehabilitation, manual therapy, activity modification, lifestyle measures and ongoing clinical review.

Not every patient is an appropriate candidate for every orthobiologic treatment. During your consultation, your practitioner will discuss whether a biological therapy is suitable for your condition, together with the expected rehabilitation, potential benefits, known limitations, possible risks, costs and alternative treatment options.

As with all healthcare interventions, individual responses vary and no treatment can guarantee a specific clinical outcome.